Trial Outcomes & Findings for In Situ Caries Model of Fluoride Toothpastes (NCT NCT01005966)

NCT ID: NCT01005966

Last Updated: 2013-07-29

Results Overview

SMH recovery test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Difference in percent SMH recovery was calculated by comparing study NaF toothpaste (1426ppmF) with reference AmF toothpaste (1400ppmF).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

65 participants

Primary outcome timeframe

Baseline to 14 days

Results posted on

2013-07-29

Participant Flow

Participants were recruited at the clinical site.

83 participants were screened and 18 participants did not meet the study criteria thus 65 participants were enrolled into the study. The subjects were randomized to receive all 5 study treatments in a pre-determined computerized randomised order as per a typical cross-over design.

Participant milestones

Participant milestones
Measure
Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]
Study toothpaste containing sodium fluoride/ silica (1426ppm fluoride as NaF)
Amine Fluoride(AmF) Toothpaste (1400ppmF)
Reference toothpaste containing amine fluoride (1400ppm fluoride as AmF)
Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)
Reference toothpaste containing sodium monofluorophosphate and sodium fluoride (1450ppmF - 1000ppmF as NaMFP and 450ppmF as NaF)
NaF Toothpaste (675ppmF)
Study toothpaste containing sodium fluoride and silica (675ppmF as NaF)
Placebo Toothpaste (0ppmF)
Placebo fluoride free toothpaste
Treatment Period 1 (14 Days)
STARTED
13
13
13
13
13
Treatment Period 1 (14 Days)
COMPLETED
11
13
12
13
13
Treatment Period 1 (14 Days)
NOT COMPLETED
2
0
1
0
0
Washout Period 1 (4 Days)
STARTED
11
13
12
13
13
Washout Period 1 (4 Days)
COMPLETED
11
13
12
12
13
Washout Period 1 (4 Days)
NOT COMPLETED
0
0
0
1
0
Treatment Period 2 (14 Days)
STARTED
13
13
12
12
11
Treatment Period 2 (14 Days)
COMPLETED
13
12
10
11
11
Treatment Period 2 (14 Days)
NOT COMPLETED
0
1
2
1
0
Washout Period 2 (4 Days)
STARTED
13
12
10
11
11
Washout Period 2 (4 Days)
COMPLETED
13
12
10
11
11
Washout Period 2 (4 Days)
NOT COMPLETED
0
0
0
0
0
Treatment Period 3 (14 Days)
STARTED
12
8
12
13
12
Treatment Period 3 (14 Days)
COMPLETED
12
7
12
13
11
Treatment Period 3 (14 Days)
NOT COMPLETED
0
1
0
0
1
Washout Period 3 ( 4 Days)
STARTED
12
7
12
13
11
Washout Period 3 ( 4 Days)
COMPLETED
12
7
12
13
11
Washout Period 3 ( 4 Days)
NOT COMPLETED
0
0
0
0
0
Treatment Period 4 (14 Days)
STARTED
10
11
11
10
13
Treatment Period 4 (14 Days)
COMPLETED
10
10
11
10
12
Treatment Period 4 (14 Days)
NOT COMPLETED
0
1
0
0
1
Washout Period 4 (4 Days)
STARTED
10
10
11
10
12
Washout Period 4 (4 Days)
COMPLETED
10
10
11
10
12
Washout Period 4 (4 Days)
NOT COMPLETED
0
0
0
0
0
Treatment Period 5 (14 Days)
STARTED
9
12
11
11
10
Treatment Period 5 (14 Days)
COMPLETED
9
12
11
11
10
Treatment Period 5 (14 Days)
NOT COMPLETED
0
0
0
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]
Study toothpaste containing sodium fluoride/ silica (1426ppm fluoride as NaF)
Amine Fluoride(AmF) Toothpaste (1400ppmF)
Reference toothpaste containing amine fluoride (1400ppm fluoride as AmF)
Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)
Reference toothpaste containing sodium monofluorophosphate and sodium fluoride (1450ppmF - 1000ppmF as NaMFP and 450ppmF as NaF)
NaF Toothpaste (675ppmF)
Study toothpaste containing sodium fluoride and silica (675ppmF as NaF)
Placebo Toothpaste (0ppmF)
Placebo fluoride free toothpaste
Treatment Period 1 (14 Days)
Adverse Event
1
0
0
0
0
Treatment Period 1 (14 Days)
Protocol Violation
1
0
1
0
0
Washout Period 1 (4 Days)
Withdrawal by Subject
0
0
0
1
0
Treatment Period 2 (14 Days)
Adverse Event
0
1
1
0
0
Treatment Period 2 (14 Days)
Protocol Violation
0
0
0
1
0
Treatment Period 2 (14 Days)
Withdrawal by Subject
0
0
1
0
0
Treatment Period 3 (14 Days)
Protocol Violation
0
1
0
0
1
Treatment Period 4 (14 Days)
Protocol Violation
0
1
0
0
0
Treatment Period 4 (14 Days)
Other Reason
0
0
0
0
1

Baseline Characteristics

In Situ Caries Model of Fluoride Toothpastes

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Randomized Participants
n=65 Participants
All randomized participants who received at least one dose of the study treatments or who have been evaluated for AEs were included.
Age Continuous
67.0 years
STANDARD_DEVIATION 9.97 • n=5 Participants
Sex: Female, Male
Female
41 Participants
n=5 Participants
Sex: Female, Male
Male
24 Participants
n=5 Participants
Region of Enrollment
United States
65 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline to 14 days

Population: Per protocol (PP) population: All randomized participants who received at least one dose of the study treatments and provided at least one measurement SMH. Participants without any major protocol violations in given study treatment period were included in the PP population.

SMH recovery test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Difference in percent SMH recovery was calculated by comparing study NaF toothpaste (1426ppmF) with reference AmF toothpaste (1400ppmF).

Outcome measures

Outcome measures
Measure
NaF Toothpaste (1426ppmF)
n=56 Participants
Study toothpaste containing NaF/ silica (1426ppmF)
AmF Toothpaste (1400ppmF)
n=57 Participants
Reference toothpaste containing AmF (1400ppmF)
NaMFP/NaF Toothpaste (1450ppmF)
Reference toothpaste containing NaMFP/NaF (1450ppmF- 1000ppmF as NaMFP and 450ppmF as NaF)
NaF Toothpaste (675ppmF)
Toothpaste containing NaF/silica (675ppmF)
Placebo Toothpaste (0ppmF)
Placebo - fluoride free toothpaste
Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF)
38.05 Percentage SMHR
Standard Error 2.52
41.06 Percentage SMHR
Standard Error 2.53

SECONDARY outcome

Timeframe: Baseline to 14 days

Population: PP population: All randomized participants who received at least one dose of the study treatments or provided at least one measurement SMH. Participants without any major protocol violations in given study treatment period were included in the PP population.

SMH test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Differences in percent SMH recovery due to study and reference toothpastes were calculated.

Outcome measures

Outcome measures
Measure
NaF Toothpaste (1426ppmF)
n=56 Participants
Study toothpaste containing NaF/ silica (1426ppmF)
AmF Toothpaste (1400ppmF)
n=57 Participants
Reference toothpaste containing AmF (1400ppmF)
NaMFP/NaF Toothpaste (1450ppmF)
n=58 Participants
Reference toothpaste containing NaMFP/NaF (1450ppmF- 1000ppmF as NaMFP and 450ppmF as NaF)
NaF Toothpaste (675ppmF)
n=59 Participants
Toothpaste containing NaF/silica (675ppmF)
Placebo Toothpaste (0ppmF)
n=59 Participants
Placebo - fluoride free toothpaste
Percent SMH Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste (1400ppm F) and Placebo (0ppmF)
38.05 Percentage SMHR
Standard Error 2.52
41.06 Percentage SMHR
Standard Error 2.53
33.48 Percentage SMHR
Standard Error 2.49
29.08 Percentage SMHR
Standard Error 2.50
14.49 Percentage SMHR
Standard Error 2.48

SECONDARY outcome

Timeframe: Baseline to 14 days

Population: PP population: All randomized participants who received at least one dose of the study treatments or provided at least one significant measurement of fluoride uptake. Participants without any major protocol violations in given study treatment period were included in the PP population.

Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.

Outcome measures

Outcome measures
Measure
NaF Toothpaste (1426ppmF)
n=56 Participants
Study toothpaste containing NaF/ silica (1426ppmF)
AmF Toothpaste (1400ppmF)
n=57 Participants
Reference toothpaste containing AmF (1400ppmF)
NaMFP/NaF Toothpaste (1450ppmF)
n=58 Participants
Reference toothpaste containing NaMFP/NaF (1450ppmF- 1000ppmF as NaMFP and 450ppmF as NaF)
NaF Toothpaste (675ppmF)
n=59 Participants
Toothpaste containing NaF/silica (675ppmF)
Placebo Toothpaste (0ppmF)
n=59 Participants
Placebo - fluoride free toothpaste
Change From Baseline in Enamel Fluoride Uptake Potential
2342.35 micrograms (μg)* F/centimeters(cm)^2
Standard Error 123.65
2305.11 micrograms (μg)* F/centimeters(cm)^2
Standard Error 123.83
1809.74 micrograms (μg)* F/centimeters(cm)^2
Standard Error 121.83
1649.44 micrograms (μg)* F/centimeters(cm)^2
Standard Error 121.93
462.95 micrograms (μg)* F/centimeters(cm)^2
Standard Error 120.92

Adverse Events

NaF Toothpaste (1426ppmF)

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

AmF Toothpaste (1400ppmF)

Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths

NaMFP/ NaF Toothpaste (1450ppmF)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

NaF Toothpaste (675ppmF)

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Placebo Toothpaste (0ppmF)

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Overall

Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
NaF Toothpaste (1426ppmF)
n=57 participants at risk
Study toothpaste containing NaF/ silica (1426ppmF)
AmF Toothpaste (1400ppmF)
n=57 participants at risk
Reference toothpaste containing AmF (1400ppmF)
NaMFP/ NaF Toothpaste (1450ppmF)
n=59 participants at risk
Reference toothpaste containing NaMFP/ NaF (1450ppmF - 1000ppmF as NaMFP and 450ppmF as NaF)
NaF Toothpaste (675ppmF)
n=59 participants at risk
Toothpaste containing NaF/ silica (675ppmF)
Placebo Toothpaste (0ppmF)
n=59 participants at risk
Placebo: fluoride free toothpaste
Overall
n=65 participants at risk
Infections and infestations
Nasopharyngitis
1.8%
1/57 • Number of events 1 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
8.8%
5/57 • Number of events 5 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
0.00%
0/59 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
5.1%
3/59 • Number of events 3 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
3.4%
2/59 • Number of events 2 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
15.4%
10/65 • Number of events 11 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

  • Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER